Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FEMY NASDAQ:LUCY NASDAQ:POAI NASDAQ:TMDIF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.39+1.9%$0.42$0.31▼$1.11$23.37M-2.261.96 million shs1.65 million shsLUCYInnovative Eyewear$1.04$1.05$0.90▼$4.97$6.66M2.788,070 shs88,111 shsPOAIPredictive Oncology$6.97+5.0%$4.58$0.71▼$16.54$20.19M1.35473,545 shs271,863 shsTMDIFTitan Medical$0.19-7.2%$0.27$0.03▼$1.00$3.73M1.2674,785 shs30,664 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys+1.95%-11.64%+3.78%-32.09%-63.49%LUCYInnovative Eyewear0.00%+1.96%0.00%-7.14%-65.68%POAIPredictive Oncology+1.68%+16.49%+11.97%+253.19%-51.09%TMDIFTitan Medical-4.06%-4.36%-39.58%-26.15%-27.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.39+1.9%$0.42$0.31▼$1.11$23.37M-2.261.96 million shs1.65 million shsLUCYInnovative Eyewear$1.04$1.05$0.90▼$4.97$6.66M2.788,070 shs88,111 shsPOAIPredictive Oncology$6.97+5.0%$4.58$0.71▼$16.54$20.19M1.35473,545 shs271,863 shsTMDIFTitan Medical$0.19-7.2%$0.27$0.03▼$1.00$3.73M1.2674,785 shs30,664 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys+1.95%-11.64%+3.78%-32.09%-63.49%LUCYInnovative Eyewear0.00%+1.96%0.00%-7.14%-65.68%POAIPredictive Oncology+1.68%+16.49%+11.97%+253.19%-51.09%TMDIFTitan Medical-4.06%-4.36%-39.58%-26.15%-27.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFEMYFemasys 2.50Moderate Buy$5.331,278.12% UpsideLUCYInnovative Eyewear 1.00SellN/AN/APOAIPredictive Oncology 1.00SellN/AN/ATMDIFTitan Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LUCY, POAI, FEMY, and TMDIF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/1/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026LUCYInnovative Eyewear Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/3/2026FEMYFemasys Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$1.50(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFEMYFemasys$2.29M10.21N/AN/A$0.12 per share3.23LUCYInnovative Eyewear$2.66M2.50N/AN/A$1.31 per share0.79POAIPredictive Oncology$1.66M14.21N/AN/A($0.46) per share-15.15TMDIFTitan Medical$17.63M1.20$9.25 per share0.02$1.05 per share0.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFEMYFemasys-$18.63M-$0.27N/AN/AN/A-521.97%-258.08%-73.72%8/12/2026 (Estimated)LUCYInnovative Eyewear-$7.59M-$1.69N/AN/AN/A-272.42%-83.37%-76.02%8/13/2026 (Estimated)POAIPredictive Oncology-$12.66M-$13.50N/AN/AN/A-5,065.23%-732.73%-235.55%N/ATMDIFTitan Medical$6.95M$0.05N/AN/AN/AN/A-82.31%-51.47%N/ALatest LUCY, POAI, FEMY, and TMDIF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LUCYInnovative Eyewear-$0.47-$0.37+$0.10-$0.37$0.70 million$0.77 million5/8/2026Q1 2026FEMYFemasys-$0.0667$0.0049+$0.0716N/A$0.77 million$0.42 million3/31/2026Q4 2025FEMYFemasys-$0.0833-$0.01+$0.0733-$0.01$1.06 million$0.81 million3/25/2026Q4 2025LUCYInnovative Eyewear-$0.43-$0.28+$0.15-$0.28$1.20 million$0.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFEMYFemasysN/AN/AN/AN/AN/ALUCYInnovative EyewearN/AN/AN/AN/AN/APOAIPredictive OncologyN/AN/AN/AN/AN/ATMDIFTitan MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFEMYFemasys0.533.911.98LUCYInnovative EyewearN/A8.026.09POAIPredictive OncologyN/A0.010.01TMDIFTitan MedicalN/A3.733.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFEMYFemasys65.27%LUCYInnovative Eyewear0.96%POAIPredictive Oncology9.04%TMDIFTitan Medical0.03%Insider OwnershipCompanyInsider OwnershipFEMYFemasys7.55%LUCYInnovative Eyewear1.66%POAIPredictive Oncology1.21%TMDIFTitan Medical0.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFEMYFemasys3060.39 million55.83 millionNot OptionableLUCYInnovative Eyewear96.40 million6.30 millionNot OptionablePOAIPredictive Oncology303.39 million3.35 millionNot OptionableTMDIFTitan Medical50114.04 million4.56 millionNot OptionableLUCY, POAI, FEMY, and TMDIF HeadlinesRecent News About These CompaniesTitan Medical Group Launches Titan Workforce Solutions: Launches to Transform Healthcare StaffingApril 29, 2025 | businesswire.comTitan Nurse Staffing, LLC and Titan Medical Group, LLC Announce Merger to Streamline Healthcare Staffing ServicesApril 29, 2025 | businesswire.comTitan MRI acquires High Field MRI, expanding Titan MRI's service to North Central FloridaDecember 3, 2024 | msn.comAttack on Titan movie release date, trailer, changes, and everything else we know about The Last AttackNovember 6, 2024 | gamesradar.comGConavi Medical Corp. (formerly “Titan Medical Inc.”) Completes Business CombinationOctober 11, 2024 | globenewswire.comTitan Announces the Closing of Conavi's Private Placement of Subscription Receipts and Provides Update on the TransactionOctober 8, 2024 | globenewswire.comTitan Announces Resignations of DirectorsOctober 2, 2024 | globenewswire.comTitan Reports Voting Results from 2023 Annual General and Special MeetingSeptember 30, 2024 | globenewswire.comTitan Medical begins process to move to the TSX Venture ExchangeSeptember 30, 2024 | globenewswire.comConavi Medical Shareholders Approve the Proposed Amalgamation Between Titan and ConaviSeptember 26, 2024 | globenewswire.comProxy Deadline Thursday September 26, 2024September 25, 2024 | globenewswire.comProxy Advisor Glass, Lewis & Co., Recommends Titan Shareholders Vote FOR the Amalgamation Between Titan and ConaviSeptember 19, 2024 | globenewswire.comA key employee says the Titan sub tragedy could have been preventedSeptember 18, 2024 | postregister.comPTitan Announces Conavi Medical to Present Overview at Titan Q&A SessionSeptember 16, 2024 | globenewswire.comIndependent Proxy Advisor, Institutional Shareholder Services (“ISS”), Recommends Titan Shareholders Vote FOR the Amalgamation Between Titan and ConaviSeptember 16, 2024 | globenewswire.comTitan Announces Q&A Session with ShareholdersSeptember 9, 2024 | globenewswire.comTitan Announces Filing of the Management Information Circular.September 6, 2024 | globenewswire.comTitan Medical | Morning BlendSeptember 3, 2024 | msn.comTitan Medical Inc. (QTNA.SG)August 24, 2024 | finance.yahoo.comTitan Medical Reports Operating and Financial Results for the Second Quarter 2024August 15, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLUCY, POAI, FEMY, and TMDIF Company DescriptionsFemasys NASDAQ:FEMY$0.39 +0.01 (+1.95%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$0.38 -0.01 (-1.81%) As of 05/29/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Innovative Eyewear NASDAQ:LUCY$1.04 0.00 (0.00%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$1.04 +0.00 (+0.10%) As of 05/29/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.Predictive Oncology NASDAQ:POAI$6.97 +0.33 (+4.97%) As of 05/29/2026Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.Titan Medical NASDAQ:TMDIF$0.18 -0.01 (-7.22%) As of 05/29/2026Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds These 3 Software Stocks Are Buying Back Shares Hand Over Fist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
